The dual barriers to biosimilar competition: A comparative analysis of US patent thickets and EU supplementary protection certificates
Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Published online on February 11, 2026
Abstract
Journal of Generic Medicines, Volume 22, Issue 1, Page 53-57, March 2026.
The timely market entry of biosimilar medicines, crucial for healthcare cost reduction, is significantly impeded by distinct intellectual property (IP) strategies employed by originator pharmaceutical companies in the United States (US) and the European ...
The timely market entry of biosimilar medicines, crucial for healthcare cost reduction, is significantly impeded by distinct intellectual property (IP) strategies employed by originator pharmaceutical companies in the United States (US) and the European ...